JP2023538669A5 - - Google Patents
Info
- Publication number
- JP2023538669A5 JP2023538669A5 JP2023513103A JP2023513103A JP2023538669A5 JP 2023538669 A5 JP2023538669 A5 JP 2023538669A5 JP 2023513103 A JP2023513103 A JP 2023513103A JP 2023513103 A JP2023513103 A JP 2023513103A JP 2023538669 A5 JP2023538669 A5 JP 2023538669A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- formulation
- buffer
- antibody construct
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063069432P | 2020-08-24 | 2020-08-24 | |
| US63/069,432 | 2020-08-24 | ||
| US202163197020P | 2021-06-04 | 2021-06-04 | |
| US63/197,020 | 2021-06-04 | ||
| PCT/US2021/047181 WO2022046651A1 (en) | 2020-08-24 | 2021-08-23 | Pharmaceutical formulation comprising a bite, bispecific antibody, and methionine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023538669A JP2023538669A (ja) | 2023-09-08 |
| JP2023538669A5 true JP2023538669A5 (enExample) | 2024-08-30 |
Family
ID=78000768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513103A Pending JP2023538669A (ja) | 2020-08-24 | 2021-08-23 | Ｂｉｔｅ、二重特異性抗体、及びメチオニンを含む医薬製剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230348596A1 (enExample) |
| EP (1) | EP4200333A1 (enExample) |
| JP (1) | JP2023538669A (enExample) |
| KR (1) | KR20230058432A (enExample) |
| AU (1) | AU2021330845A1 (enExample) |
| BR (1) | BR112023002923A2 (enExample) |
| CA (1) | CA3185960A1 (enExample) |
| CL (1) | CL2023000486A1 (enExample) |
| IL (1) | IL299242A (enExample) |
| MX (1) | MX2023002280A (enExample) |
| WO (1) | WO2022046651A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4346778A1 (en) * | 2021-06-01 | 2024-04-10 | Amgen Inc. | Accelerated method of making lyophilized protein formualtions |
| TW202421650A (zh) * | 2022-09-14 | 2024-06-01 | 美商安進公司 | 雙特異性分子穩定組成物 |
| WO2025080688A1 (en) | 2023-10-12 | 2025-04-17 | Amgen Inc. | Compositions of bispecific antibody constructs to human dll3 and human cd3 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| CA2409991A1 (en) | 2000-05-24 | 2001-11-29 | Imclone Systems Incorporated | Bispecific immunoglobulin-like antigen binding proteins and method of production |
| EP1786918A4 (en) | 2004-07-17 | 2009-02-11 | Imclone Systems Inc | NEW BISPECIFIC ANTIBODY TETRAVALENT |
| TW200806317A (en) * | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
| KR20100052545A (ko) | 2007-08-28 | 2010-05-19 | 바이오겐 아이덱 엠에이 인코포레이티드 | Ｉｇｆ―１ｒ의 다중 에피토프에 결합하는 조성물 |
| AR078161A1 (es) * | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| EP3699195A3 (en) | 2014-03-28 | 2020-11-04 | Xencor, Inc. | Bispecific antibodies that bind to cd38 and cd3 |
| SMT202500367T1 (it) * | 2017-02-02 | 2025-11-10 | Amgen Res Munich Gmbh | Composizione farmaceutica a basso ph comprendente costrutti di anticorpo che reclutano le cellule t |
| UY37726A (es) * | 2017-05-05 | 2018-11-30 | Amgen Inc | Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración mejorados |
| WO2019020745A1 (en) * | 2017-07-28 | 2019-01-31 | F. Hoffmann-La Roche Ag | Bispecific antibody formulation |
| MA51747A (fr) * | 2018-02-08 | 2020-12-16 | Amgen Inc | Formulation d'anticorps pharmaceutique à ph faible |
| CN119857138A (zh) * | 2018-09-13 | 2025-04-22 | 豪夫迈·罗氏有限公司 | Csf-1r抗体制剂 |
| WO2020072306A1 (en) * | 2018-10-01 | 2020-04-09 | Amgen Inc. | Methods for reducing aggregation of bispecific antibodies |
-
2021
- 2021-08-23 EP EP21783077.7A patent/EP4200333A1/en active Pending
- 2021-08-23 AU AU2021330845A patent/AU2021330845A1/en active Pending
- 2021-08-23 MX MX2023002280A patent/MX2023002280A/es unknown
- 2021-08-23 BR BR112023002923A patent/BR112023002923A2/pt unknown
- 2021-08-23 US US18/022,685 patent/US20230348596A1/en active Pending
- 2021-08-23 JP JP2023513103A patent/JP2023538669A/ja active Pending
- 2021-08-23 CA CA3185960A patent/CA3185960A1/en active Pending
- 2021-08-23 IL IL299242A patent/IL299242A/en unknown
- 2021-08-23 WO PCT/US2021/047181 patent/WO2022046651A1/en not_active Ceased
- 2021-08-23 KR KR1020237009363A patent/KR20230058432A/ko active Pending
-
2023
- 2023-02-17 CL CL2023000486A patent/CL2023000486A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023538669A5 (enExample) | ||
| JP7446356B2 (ja) | 抗ｒｓｖモノクローナル抗体製剤 | |
| EP1409018B1 (en) | Stable lyophilized pharmaceutical formulation the igg antibody daclizumab | |
| JP6041673B2 (ja) | リポペプチド組成物および関連する方法 | |
| JP2023018090A (ja) | 高濃度のタンパク質ベース治療薬を含有する医薬組成物における安定化化合物としてのアミノ酸の使用 | |
| US20160375133A1 (en) | Methods for producing high concentration lyophilized pharmaceutical formulations | |
| JP2021512881A5 (enExample) | ||
| WO2010146598A2 (en) | Stable, dried rotavirus vaccine, compositions and process for preparation thereof | |
| KR20090021298A (ko) | 항-ｅｇｆｒ 항체의 동결건조 제제 | |
| JP2005513110A (ja) | Ｅｇｆ受容体に対する抗体を含む凍結乾燥製剤 | |
| DK1993557T3 (en) | NOVEL epoprostenol DEFINITION AND MANUFACTURING METHOD THEREOF | |
| JP2012121894A (ja) | Ｉｌ−１アンタゴニスト製剤 | |
| JP2023539476A5 (enExample) | ||
| JP2024521329A5 (enExample) | ||
| JP2023524445A5 (enExample) | ||
| US20040247588A1 (en) | Formulations of modified antibodies and methods of making the same | |
| JP2022518441A5 (enExample) | ||
| JP2023524444A5 (enExample) | ||
| WO2000076480A9 (en) | Pharmaceutical materials and methods for their preparation and use | |
| JP2024523443A5 (enExample) | ||
| JP2025503483A5 (enExample) | ||
| RU2024121592A (ru) | Лиофилизированная композиция, содержащая слитый белок, включающий α-галактозидазу А | |
| HK40011725A (en) | Anti-rsv monoclonal antibody formulation | |
| EA048838B1 (ru) | Состав на основе моноклонального антитела к rsv | |
| TH60899A (th) | ยาเตรียมชนิดแห้งแบบเยือกแข็งซึ่งประกอบรวมด้วยแอนติบอดี้ที่ต่อต้าน egf รีเซพเตอร์ |